Fig. 1

20

9

-200

0.001


TN-I

Signal

-0.01

1200 -1000 800 900 69 200

1.0-1



20

2000 4000

0009

-0.00001

FI

10000 8000

Signal

-0.0001

10.001 **10.01**

16000 14000




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8




Fig. 9





Fig. 10










Fig. 11


Fig. 12

















Fig.13




Fig. 14




Fig. 15A




Fig. 15B






Fig. 16








Fig. 17




Fig. 18





Fig. 19

Fig. 20


Significant decrease of mtDNA in PBMC



Weeks after start of therapy


Fig. 21





days since start treatment

Fig. 22






Fig. 23

WK16

WK14

¥712

₩




Fig. 24

Percentage of patients changing ART because of adverse effects Adverse effects of antiretroviral therapy (results from the ATHENA-study in the Netherlands)





Fig. 25



DNA-NASBA amplification

Fig. 26

